Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Leveraging Telemedicine to Improve Guideline-Directed Medical Therapy Use and Outcomes Among Rural Patients With Heart Failure (RURAL-HF)

12. november 2026 oppdatert av: Ambarish Pandey, University of Michigan

Leveraging Telemedicine to Improve Guideline-Directed Medical Therapy Use and Outcomes Among Rural Patients With Heart Failure - the RURAL-HF Trial

The goal of this clinical trial is to learn if a new way of adjusting heart failure medicines can improve health in adults with heart failure who live in rural areas. This study tests whether remotely helping local doctors safely raise these doses faster can improve health over the first 3 months after leaving the hospital.

The main questions it aims to answer are:

  • Does the new approach help participants live longer, avoid needing a heart transplant or heart pump, stay out of the hospital for heart failure, and feel better day to day, over 6 months?
  • Do more participants take all their recommended heart failure medicines, at the best doses, by 6 months?
  • Does the new approach improve quality of life and daily activity, and how well does it work in everyday rural health care?

Participants will be placed by chance, like flipping a coin, into 1 of 2 groups: home monitoring alone or home monitoring plus medication optimization support. In the home monitoring alone group, participants' own doctors will manage their medicines as usual. In the medicine support group, heart failure specialists on the study team will use home readings and results from NT-proBNP blood tests, to send medicine advice to participants' own doctors. Researchers will compare the 2 groups to see if medicine support improves health and quality of life.

Participants will:

  • Use a scale, blood pressure cuff, and activity tracker at home for 3 months
  • May have routine blood tests ordered by their own doctor about 2 and 6 weeks after joining, if they are in the medicine support group
  • Complete video or phone study visits when they join, at 3 months, and at 6 months
  • Answer questions about their heart failure symptoms and quality of life at each visit
  • Some participants may also be asked to take part in an interview about their experience.

Studieoversikt

Detaljert beskrivelse

Background and Rationale:

Rural communities experience persistent and widening disparities in cardiovascular outcomes, driven by adverse social determinants of health, limited access to specialty care, and structural barriers to timely treatment. Heart failure (HF) exemplifies these inequities, with rural patients experiencing higher mortality and poorer access to acute and longitudinal care despite a growing and aging HF population. Although guideline-directed medical therapy (GDMT) substantially improves outcomes in both heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF), real-world uptake and dose optimization remain low, particularly in rural settings, largely due to limited access to cardiac care, fragmented follow-up, and implementation challenges rather than true contraindications.

Telemedicine and remote patient monitoring (RPM) offer a practical strategy to address these barriers by expanding access to specialty input, enabling close physiologic monitoring, and supporting safe titration of GDMT medications without the need for frequent in-person visits. While early studies suggest that telehealth-enabled GDMT optimization can improve therapy uptake and outcomes, these approaches have not been rigorously evaluated in rural populations. This study addresses a critical evidence gap by testing a telemedicine-enabled, remote monitoring-supported strategy tailored to rural healthcare delivery, with the goal of improving GDMT optimization and reducing rural-urban disparities in HF care.

Study Design:

RURAL-HF is a randomized, open-label, Type 1 hybrid effectiveness-implementation trial comparing RPM alone vs. RPM combined with NT-proBNP-guided, provider-to-provider GDMT up-titration in patients recently hospitalized for HF in rural communities. Both arms receive remote monitoring devices for the first 90 days, isolating the effect of the NT-proBNP-guided GDMT titration intervention itself. The simultaneous collection of GDMT prescription, clinical, and implementation outcomes will inform future use and scalability should the intervention prove effective.

Participants will be enrolled at discharge from the index HF hospitalization or within 2 weeks of discharge. Participants will be randomly assigned 1:1 using a computerized algorithm. Block randomization will be performed by trial site and stratified by HF subtype (HFrEF/HFmrEF vs HFpEF) using REDCap. All recruitment and informed consent procedures will be conducted virtually using secure, HIPAA-compliant telehealth platforms. Blinding is not feasible because up-titration recommendations must be provided on the basis of physiologic data from remote monitoring.

Remote Patient Monitoring (Both Arms):

All participants, regardless of study arm, receive a cellular-connected device kit at enrollment. The kit includes a cellular-connected weight scale, a cellular-connected blood pressure and heart rate monitor, and a wrist-based watch that measures physical activity (step count). Devices arrive pre-configured and connect automatically to existing 4G/5G cellular networks, with no setup or home internet access required. This cellular-based approach enhances generalizability to rural populations by leveraging existing cellular tower infrastructure rather than requiring home broadband.

Participants are prompted to submit weight, heart rate, and blood pressure twice weekly for the first 6 weeks, decreasing to once weekly if no alert occurs, and returning to twice weekly if a new alert occurs. Remote monitoring alerts are reviewed, actioned, and closed by the study team. Active remote monitoring occurs from enrollment through 90 days for both arms.

RPM + NT-proBNP + GDMT Up-titration Arm:

The study team will provide GDMT initiation and titration recommendations to the participant's outpatient care team (primary care provider or cardiologist) on the basis of review of remote monitoring data. Recommendations will be delivered through asynchronous communication via the electronic health record, and the study team will offer at least one synchronous consultation (video or telephone) during the initial 90-day titration period. During the first 90 days post-discharge, the study team will review biometric data at least weekly and provide specific, evidence-based recommendations at one-to-two-week intervals until optimal or maximally tolerated GDMT is achieved. Recommendations will include specific medication suggestions (drug, dose, titration schedule) and laboratory-based monitoring instructions.

The study will employ a structured protocol integrating NT-proBNP levels, potassium, eGFR, and physiological safety parameters to guide GDMT optimization. Laboratory monitoring, including NT-proBNP and basic metabolic panels, will occur at weeks 2 and 6 as part of routine clinical care. NT-proBNP levels that remain stable or decline compared with pre-discharge baseline indicate safe conditions for beta-blocker up-titration, while NT-proBNP increases of more than 10% above pre-discharge levels will suggest withholding beta-blocker up-titration and instead increasing diuretic therapy to address potential worsening congestion. The participant's outpatient care team will implement recommendations through clinical encounters conducted according to their standard practice patterns. This approach is informed by STRONG-HF, which was associated with significantly greater uptake of GDMT and reduced risk of HF hospitalization or death at 180 days.

RPM Alone Arm:

Participants in the RPM alone arm receive the same device kit and remote monitoring for 90 days but do not have NT-proBNP testing or study-team GDMT titration recommendations. Remote monitoring alerts for this arm will be sent to the provider without recommendations for GDMT up-titration. Providers will receive general education surrounding GDMT use for patients with HF, and GDMT management is otherwise delivered according to standard community practice patterns.

Follow-up:

There will be three virtual study visits during the 6-month study period: a screening and baseline visit at enrollment, a 3-month follow-up visit coinciding with the end of the active 90-day RPM/GDMT titration period, and an end-of-study visit at 6 months. Between 90 days and 6 months, participants in both study arms will receive standard care from their outpatient providers without active study team intervention.

Statistical Analysis:

The primary endpoint will be analyzed using a stratified (by HF subtype), hierarchical win ratio approach, in which every participant in the RPM + NT-proBNP + GDMT arm is compared with every participant in the RPM alone arm over a shared follow-up time. The primary endpoint components and their hierarchy were determined after a survey of patients with HF, who noted that preventing mortality was the most important treatment outcome, followed by improving quality of life and avoiding hospitalization. A total of 598 participants will provide 80% power to detect a weighted stratified win ratio of 1.34 using a one-sided stratified win ratio Z-test with a Type I error rate of 0.025. The intent-to-treat population will include all randomized participants, analyzed according to their assigned treatment group. Pre-specified subgroup analyses of the primary endpoint will be conducted by sex, type of HF (HFrEF/HFmrEF vs. HFpEF), and racial/ethnic group.

Implementation Evaluation:

Implementation will be evaluated using the RE-AIM framework (reach, effectiveness, adoption, implementation fidelity, and maintenance), guided by the Implementation Research Logic Model and the Consolidated Framework for Implementation Research. An explanatory sequential mixed-methods design will combine quantitative implementation metrics with semi-structured key informant interviews with patients and caregivers (n=36, equally across study arms) and providers (n=12). Interviews will be audio or video recorded, transcribed verbatim, de-identified, and analyzed using rapid thematic analysis in Dedoose.

Studietype

Intervensjonell

Registrering (Antatt)

600

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • Michigan
      • Ann Arbor, Michigan, Forente stater, 48109
        • University of Michigan
        • Hovedetterforsker:
          • Ambarish Pandey, MD
        • Ta kontakt med:
    • Texas
      • Plano, Texas, Forente stater, 75093
        • Baylor Scott & White Cardiac Consultants - Plano
        • Ta kontakt med:
        • Hovedetterforsker:
          • Neil Keshvani, MD

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Age > 18 years old
  • Hospitalization for heart failure (HF) with intravenous diuretic use, with randomization within 14 days of discharge
  • Residing in a rural area (home address in a rural area as defined by the Federal Office of Rural Health Policy)
  • Established outpatient care (cardiology or primary care physician) at the participating sites
  • Eligible to receive at least 2 of 4 guideline-directed medical therapy (GDMT) classes for HF with reduced or mildly reduced ejection fraction (HFrEF or HFmrEF; beta-blocker, ACE inhibitor/ARB/ARNi, MRA, SGLT2 inhibitor), or at least 1 of 3 GDMT classes for HF with preserved ejection fraction (HFpEF; ACE inhibitor/ARB/ARNi, MRA, SGLT2 inhibitor), and not on target doses of these medication classes
  • Able to communicate with the study team via telephone or videoconference for study-related assessments and follow-up

Exclusion Criteria:

  • Stage D HF under consideration for or a recipient of advanced HF therapies, including left ventricular assist device (LVAD), heart transplant, or inotrope therapy
  • Discharge disposition to a nursing home, inpatient rehabilitation facility, or long-term care facility
  • Potassium > 5.5 mmol/L
  • End-stage kidney disease or eGFR < 25 mL/min/1.73 m²
  • Inability to provide informed consent
  • Pregnancy

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Remote patient monitoring + NT-proBNP & provider-to-provider support

Participants receive a cellular-connected device kit (weight scale, blood pressure and heart rate monitor, and wrist-worn activity tracker) with remote monitoring for 90 days following enrollment. In addition, the study team recommends NT-proBNP and basic metabolic panel testing at weeks 2 and 6, which the participant's outpatient care team may obtain as part of routine clinical care. The study team reviews biometric and laboratory data at least weekly and delivers specific, evidence-based GDMT initiation and titration recommendations (drug, dose, titration schedule, and laboratory monitoring instructions) to the participant's outpatient care team through asynchronous electronic health record communication at one-to-two-week intervals throughout the 90-day titration period. At least one synchronous video or telephone consultation is offered, with additional consultations available at the provider's preference. The participant's outpatient care team implements all medication changes.

The study team reviews remote monitoring data at least weekly, along with NT-proBNP and basic metabolic panel results from testing recommended at weeks 2 and 6 and obtained as part of routine clinical care. Recommendations for GDMT initiation and up-titration to optimal or maximally tolerated doses (drug, dose, titration schedule, and laboratory monitoring) are sent to the outpatient care team through the electronic health record every 1 to 2 weeks for 90 days, with at least one video or telephone consultation offered. A structured protocol integrating NT-proBNP, potassium, eGFR, blood pressure, and heart rate guides titration.

Participants receive a cellular-connected weight scale, blood pressure and heart rate monitor, and wrist-worn activity tracker that arrive pre-configured and require no home internet. Participants submit weight, heart rate, and blood pressure twice weekly for 6 weeks, then once weekly if no alerts occur. Step count is captured continuously. The study team reviews and actions alerts and contacts participants if no data are received for 7 days. Active monitoring continues for 90 days.

Aktiv komparator: Remote patient monitoring (RPM) alone

Participants receive the same cellular-connected device kit with remote monitoring for 90 days following enrollment. The study team may send safety alerts from remote monitoring to the participant's outpatient provider, without recommendations for GDMT up-titration. No recommendations for NT-proBNP testing and GDMT titration recommendations will be sent out by the study team. GDMT management, outpatient follow-up, and laboratory monitoring are delivered according to standard community practice by the participant's primary care provider or cardiologist.

Participants receive a cellular-connected weight scale, blood pressure and heart rate monitor, and wrist-worn activity tracker that arrive pre-configured and require no home internet. Participants submit weight, heart rate, and blood pressure twice weekly for 6 weeks, then once weekly if no alerts occur. Step count is captured continuously. The study team reviews and actions alerts and contacts participants if no data are received for 7 days. Active monitoring continues for 90 days.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Hierarchical Composite of All-Cause Mortality, Heart Transplantation or Ventricular-Assist Device, Heart Failure Hospitalizations, and Improvement in Kansas City Cardiomyopathy Questionnaire Score
Tidsramme: Baseline to 180 days

The primary endpoint is a hierarchical composite of all-cause mortality, heart transplantation or ventricular-assist device, HF hospitalization (yes/no), total number of HF hospitalizations, or a >5-point improvement in the Kansas City Cardiomyopathy Questionnaire (KCCQ). The endpoint will be assessed at 6 months using a stratified, hierarchical win ratio approach.

Baseline to 180 days

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Proportion of participants achieving optimal or maximally tolerated GDMT
Tidsramme: Baseline to 90 days

The proportion of participants achieving optimal or maximally tolerated GDMT will be evaluated as a secondary outcome. For participants with HFrEF or HFmrEF, target GDMT consists of optimal or maximally tolerated doses of an evidence-based beta-blocker and an ARNi (or ACE inhibitor/ARB if ARNi is not tolerated), an MRA at target dose, and an SGLT2 inhibitor. For participants with HFpEF, target GDMT consists of an optimal or maximally tolerated dose of an ARNi or ARB (preferred over ACE inhibitor) and any dose of an SGLT2 inhibitor and an MRA (finerenone or spironolactone). GDMT prescription will be assessed via electronic medical record and pharmacy review.

Baseline to 90 days
Heart Failure Collaboratory GDMT composite score
Tidsramme: Baseline to 180 days

GDMT utilization across all medication classes will also be assessed using the well-validated and prognostically meaningful composite HF Collaboratory score. The Heart Failure Collaboratory (HFC) GDMT score is a validated composite that measures overall guideline-directed medical therapy use. Points are assigned for prescription of each drug class (beta-blocker, ACEi/ARB/ARNi, MRA, and SGLT2i) and weighted by percentage of target dose. Higher scores reflect more complete therapy optimization.

Baseline to 180 days
Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) overall summary score
Tidsramme: Baseline to 180 days

Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) overall summary score. The KCCQ is a well-validated, HF-specific, patient-reported outcome measure and an FDA-endorsed measure of symptom and functional benefit. Scores range from 0 to 100, with higher scores indicating better health status.

Baseline to 180 days
Change in mean daily step count
Tidsramme: Baseline to 90 days, and baseline to 180 days

Change in mean daily step count, captured continuously via the wrist-worn activity device with remote monitoring. Step count provides an objective, continuously captured functional outcome that complements patient-reported quality of life and is less susceptible to reporting bias in this open-label design.

Baseline to 90 days, and baseline to 180 days
Implementation outcomes assessed using the RE-AIM framework
Tidsramme: Through study completion, up to 60 months

Implementation will be evaluated using the Reach, Effectiveness, Adoption, Implementation, and Maintenance (RE-AIM) framework, with implementation assessed as fidelity. To understand contextual factors influencing implementation success, an explanatory sequential mixed-methods approach will combine quantitative implementation metrics with qualitative interviews of clinicians (n=12) and patients (n=36, stratified by study arm) to explore barriers, facilitators, acceptability, and differential effectiveness across patient subgroups, including age, sex, race/ethnicity, and socioeconomic position. Real-world implementation assessment is essential for translation beyond the trial setting.

Through study completion, up to 60 months

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Ambarish Pandey, MD, University of Michigan

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Generelle publikasjoner

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. desember 2026

Primær fullføring (Antatt)

1. desember 2031

Studiet fullført (Antatt)

1. desember 2031

Datoer for studieregistrering

Først innsendt

12. november 2026

Først innsendt som oppfylte QC-kriteriene

12. november 2026

Først lagt ut (Faktiske)

18. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

18. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

12. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

IPD-planbeskrivelse

Please contact the study team.

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere